The improved function of the intestinal barrier prevents the entry of endotoxins into the liver, thus inhibiting the expression of the TLR4/NF-κB pathway, mitigating inflammation and the resulting hepatic steatosis. The gene discussed is NFKB1; the disease is fatty liver disease.